Expression of p53 Protein in Prostate Carcinoma and its Correlation with Gleason Grade

被引:1
作者
Wahid, Zakia [1 ]
Jaffer, Rozina [2 ]
Khalid, Sobia [3 ]
Khan, Haseeb Ahmed [1 ]
Riaz, Sabiha [1 ]
机构
[1] Fatima Mem Hosp, Dept Pathol, Lahore, Pakistan
[2] Rahber Med Coll, Dept Pathol, Lahore, Pakistan
[3] Univ Hlth Sci, Dept Pathol, Lahore, Pakistan
来源
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN | 2020年 / 30卷 / 06期
关键词
Prostate cancer; Immunohistochemistry; p53; protein; Gleason score; MUTANT P53;
D O I
10.29271/jcpsp.2020.6.643
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives; To determine the correlation of p53 expression with Gleason score in prostate cancer. Study Design: Descriptive study. Place and Duration of Study: Department of Pathology, Fatima Memorial Hospital, Lahore; from January 2014 to August 2016. Methodology: Thirty-seven samples of prostate carcinoma were graded using Gleason grading system. p53 expression was detected through routine immunohistochemical staining protocols and assessed semi-quantitatively using four-point scale score. The collected data was analysed statistically using Pearson's correlation coefficient. Results: Out of a sample of 37, high grade tumours were observed in 21 (57%) cases, making them the most prevalent type; while, p53 positive nuclear staining was observed in 26 (70%) cases. Within the high grade tumours, strong positive p53 expression was observed in 8 (38%) tumours; while, overexpression of p53 protein was seen in 7 (33%) cases. In contrast, overexpression of p53 was absent in low grade tumours. Conclusion: A statistically significant correlation was observed between p53 positive expression and high Gleason grade.
引用
收藏
页码:643 / 645
页数:3
相关论文
共 15 条
  • [1] Aziz Z, 2003, J Pak Med Assoc, V53, P350
  • [2] When mutants gain new powers: news from the mutant p53 field
    Brosh, Ran
    Rotter, Varda
    [J]. NATURE REVIEWS CANCER, 2009, 9 (10) : 701 - 713
  • [3] Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
    Cooperberg, Matthew R.
    Broering, Jeanette M.
    Carroll, Peter R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) : 1117 - 1123
  • [4] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386
  • [5] The role of mutant p53 in human cancer
    Goh, Amanda M.
    Coffill, Cynthia R.
    Lane, David P.
    [J]. JOURNAL OF PATHOLOGY, 2011, 223 (02) : 116 - 126
  • [6] Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
  • [7] Karaburun Paker S, 2001, Pathol Oncol Res, V7, P209
  • [8] Kaur H, 2016, ANN PATHOL LAB MED, V3
  • [9] Kehinde EO, 2008, CAN J UROL, V15, P3967
  • [10] Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer
    Kluth, Martina
    Harasimowicz, Silvia
    Burkhardt, Lia
    Grupp, Katharina
    Krohn, Antje
    Prien, Kristina
    Gjoni, Jovisa
    Hass, Thomas
    Galal, Rami
    Graefen, Markus
    Haese, Alexander
    Simon, Ronald
    Huehne-Simon, Julia
    Koop, Christina
    Korbel, Jan
    Weischenfeld, Joachim
    Huland, Hartwig
    Sauter, Guido
    Quaas, Alexander
    Wilczak, Waldemar
    Tsourlakis, Maria-Christina
    Minner, Sarah
    Schlomm, Thorsten
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (06) : 1369 - 1380